共 6 条
[1]
Isoliquiritigenin; a natural anti‐oxidant; selectively inhibits the proliferation of prostate cancer cells[J] XiaoyuZhang;Eddie DYeung;JingyingWang;Evgeniy EPanzhinskiy;ChaoTong;WenguangLi;JiLi Clinical and Experimental Pharmacology and Physiology 2010,
[2]
Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells[J] Jae InJung;EunkyungChung;Mi RaSeon;Hyun‐KyungShin;Eun JiKim;Soon SungLim;Won‐YoonChung;Kwang‐KyunPark;Jung Han YoonPark BioFactors 2008,
[3]
Angiogenesis; hypoxia and VEGF expression during tumour growth in a human xenograft tumour model[J] E.M. Hendriksen;P.N. Span;J. Schuuring;J.P.W. Peters;F.C.G.J. Sweep;A.J. van der Kogel;J. Bussink Microvascular Research 2008,
[4]
Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells[J] Tatsushi Yoshida;Mano Horinaka;Mami Takara;Mayuko Tsuchihashi;Nobuhiro Mukai;Miki Wakada;Toshiyuki Sakai Environmental Health and Preventive Medicine 2008,
[5]
Isoliquiritigenin inhibits IκB kinase activity and ROS generation to block TNF-α induced expression of cell adhesion molecules on human endothelial cells[J] Sarvesh Kumar;Amit Sharma;Babita Madan;Vandana Singhal;Balaram Ghosh Biochemical Pharmacology 2007,
[6]
Anthraquinone derivative emodin inhibits tumor-associated angiogenesis through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation[J] Tatsuya Kaneshiro;Takamitsu Morioka;Morihiko Inamine;Tatsuya Kinjo;Junya Arakaki;Itaru Chiba;Nao Sunagawa;Masumi Suzui;Naoki Yoshimi European Journal of Pharmacology 2006,

